Palumbo Wealth Management LLC Acquires New Shares in uniQure N.V. $QURE

Palumbo Wealth Management LLC bought a new stake in uniQure N.V. (NASDAQ:QURE) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 21,778 shares of the biotechnology company’s stock, valued at approximately $1,271,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in QURE. Jefferies Financial Group Inc. bought a new stake in shares of uniQure in the 2nd quarter valued at about $29,217,000. JPMorgan Chase & Co. boosted its stake in uniQure by 471.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock worth $25,199,000 after acquiring an additional 1,491,486 shares during the last quarter. Sofinnova Investments Inc. grew its holdings in uniQure by 185.5% during the second quarter. Sofinnova Investments Inc. now owns 1,558,356 shares of the biotechnology company’s stock valued at $21,723,000 after purchasing an additional 1,012,585 shares during the period. Balyasny Asset Management L.P. increased its stake in uniQure by 2,054.1% in the second quarter. Balyasny Asset Management L.P. now owns 536,968 shares of the biotechnology company’s stock valued at $7,485,000 after purchasing an additional 512,040 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its stake in uniQure by 38.6% in the second quarter. Ameriprise Financial Inc. now owns 761,948 shares of the biotechnology company’s stock valued at $10,622,000 after purchasing an additional 212,218 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

uniQure Price Performance

Shares of NASDAQ QURE opened at $24.47 on Tuesday. The company has a fifty day moving average price of $23.68 and a 200 day moving average price of $29.62. The firm has a market cap of $1.52 billion, a PE ratio of -5.57 and a beta of 0.66. The company has a current ratio of 7.12, a quick ratio of 7.12 and a debt-to-equity ratio of 0.23. uniQure N.V. has a 1-year low of $7.76 and a 1-year high of $71.50.

Insider Activity

In related news, Director Jack Kaye sold 6,390 shares of the stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $27.28, for a total transaction of $174,319.20. Following the completion of the transaction, the director directly owned 20,439 shares in the company, valued at approximately $557,575.92. This trade represents a 23.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Robert Gut sold 25,613 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $24.62, for a total value of $630,592.06. Following the completion of the sale, the director owned 32,342 shares in the company, valued at $796,260.04. The trade was a 44.19% decrease in their position. The disclosure for this sale is available in the SEC filing. 4.79% of the stock is owned by corporate insiders.

uniQure News Summary

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Upcoming catalyst — uniQure will report fourth-quarter and full‑year 2025 results before the market opens on March 2, 2026, followed by an 8:00 a.m. ET conference call. Results and management commentary could clarify revenue, commercialization progress for its hemophilia B gene therapy and development timelines for Huntington’s, ALS and other programs — a potential positive catalyst if results or guidance beat expectations. uniQure to Announce 2025 Financial Results
• Neutral Sentiment: Mixed market signals — a QuiverQuant summary highlights strong analyst interest (multiple buy/outperform ratings and a median 6‑month target around $53) but also notes heavy insider selling over the past 6 months and shifting institutional positions. Analysts’ optimism is a tailwind, but insider sales and recent portfolio churn create mixed signals for near‑term sentiment. uniQure N.V. to Report Q4 and Full Year 2025 Financial Results on March 2, 2026
• Negative Sentiment: Legal overhang — multiple plaintiff firms have filed or solicited investors for a securities‑class action covering purchases between Sept. 24 and Oct. 31, 2025, and are urging investors to contact counsel; firms include Rosen, Levi & Korsinsky, Berger Montague, Schall and DJS. They cite alleged securities‑law violations and set an April 13, 2026 lead‑plaintiff deadline. The proliferation of suits increases litigation risk, potential legal expenses and an investor overhang that can weigh on the share price until resolved. ROSEN Encourages uniQure Investors to Secure Counsel Levi & Korsinsky Class Action Notice Berger Montague Investor Alert

Wall Street Analysts Forecast Growth

QURE has been the topic of a number of recent analyst reports. Benchmark reissued a “buy” rating on shares of uniQure in a research report on Tuesday, November 4th. Mizuho dropped their price objective on uniQure from $60.00 to $33.00 and set an “outperform” rating on the stock in a research note on Monday, December 8th. The Goldman Sachs Group reduced their target price on uniQure from $56.00 to $38.00 and set a “neutral” rating on the stock in a report on Tuesday, November 4th. HC Wainwright reissued a “buy” rating and issued a $70.00 target price on shares of uniQure in a research note on Tuesday, February 10th. Finally, Stifel Nicolaus lowered their price target on uniQure from $50.00 to $40.00 and set a “buy” rating for the company in a report on Thursday, December 11th. Ten investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $58.33.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.